Stopping GLP-1 medicines: how to keep the weight off, and what the evidence says

Around half of people who start a GLP-1 medicine stop within a year. The reasons vary: cost, side effects, reaching a goal weight, or an NHS service that only prescribes for a fixed period.

The trial evidence on what happens next is consistent. On average, most of the lost weight returns, and it returns faster than it does after a diet. That is an average, not a certainty. In one large trial about one in six people kept nearly all of their weight loss a year after stopping.

The evidence on what improves your odds is thinner than provider marketing suggests, but it points in a clear direction. If you have the choice, step down rather than stop dead. Build an exercise habit before you stop, not after. Weigh yourself regularly. Decide in advance what you will do if the weight starts to return.

What happens when you stop

Four pieces of evidence carry most of the weight here. One followed trial participants for a year after treatment ended. Two are randomised trials in which some people were switched from the medicine to a placebo without knowing it. The fourth pools every relevant study.

The health gains tracked the weight. In the STEP 1 extension and SURMOUNT-4, improvements in blood pressure, blood sugar and cholesterol moved back towards where they started.

Three caveats matter.

• The trials stopped the medicine abruptly. STEP 1 also withdrew its diet and activity support at the same time. Real-world stopping can be managed better than that.
• The BMJ projection that weight returns to baseline about 1.5 years after semaglutide or tirzepatide is a model. Only eight studies covered the newer medicines, and none followed people for more than 12 months off treatment.
• Averages hide a spread. In SURMOUNT-4, 16.6% of the placebo group still held at least 80% of their weight loss a year after stopping.

One finding deserves attention because it is uncomfortable. The BMJ authors compared medicines with behavioural programmes and found regain was faster after medicines, by about 0.3 kg a month, however much weight had been lost.

Why the weight comes back

GLP-1 medicines work mainly by reducing appetite. They do not reset it. Once the medicine clears your system, which takes a few weeks for the weekly injections, hunger returns to something like its old level.

The body also pushes back against weight loss however it was achieved. A widely cited 2011 study in the New England Journal of Medicine found that hormones driving hunger were still raised, and those signalling fullness still lowered, a year after people lost weight by dieting. Regain is biology more than willpower.

Why regain should be faster after medicines than after behavioural programmes is not settled. One plausible explanation is that people who lose weight through a programme have had to practise the habits that hold it off, while the medicine does that work for you. That has not been tested directly.

What helps, ranked by evidence

The best evidence is for not stopping completely

The two strongest results in that table are not really about stopping. They are about moving to a cheaper or more convenient form of the same treatment.

In SURMOUNT-MAINTAIN, people who had lost weight on full-dose tirzepatide were randomised to stay on it, drop to 5 mg, or switch to placebo. After a year, a quarter of the 5 mg group had regained at least half their loss and needed the higher dose again. In the placebo group it was two-thirds.

In ATTAIN-MAINTAIN, people moved from a weekly injection to orforglipron (Foundayo), a daily GLP-1 tablet. Most of the weight stayed off. Both trials were funded by Eli Lilly, which makes all three products, and both ran for one year.

If cost is your reason for stopping, a lower maintenance dose may be worth pricing before you decide. Our price pages list every dose step. Whether a lower dose is suitable is a decision for your prescriber.

Exercise is the best-supported habit

The S-LiTE trial in Copenhagen was the first randomised trial to follow people after stopping both a GLP-1 medicine and an exercise programme. Participants spent a year on liraglutide, supervised exercise, both, or placebo. A year after everything ended, those who had taken liraglutide alone had regained 6 kg more than those who had only exercised. The combination group were far more likely to have kept off at least 10% of their starting weight.

There are limits. Liraglutide is an older and weaker medicine than semaglutide or tirzepatide. The exercise was supervised and structured, and the trial was small. The practical lesson still holds: the exercise habit needs to be in place before the medicine stops.

Resistance training and adequate protein are widely recommended to protect muscle during weight loss. That is sensible. A 2025 review described the evidence for them specifically in people on GLP-1 medicines as mixed, and no trial has shown that either prevents regain.

Tapering is plausible but unproven

Some providers offer a taper. The evidence behind it is one conference abstract from a digital clinic, Embla. Of 353 patients who reduced semaglutide to zero over about nine weeks while receiving coaching, 85 had data at 26 weeks, and their weight was stable.

There was no comparison group, and the people who tapered had already reached their target and chosen to stop. That is a selected group. No licence sets out a taper schedule, so this is a matter for your prescriber. Do not improvise by counting clicks on a pen.

Support alone has not been shown to slow regain

The BMJ analysis looked for a difference in regain between people who received behavioural support and those who did not. It found none. NICE still recommends follow-up support, and that is reasonable. Regular contact catches regain early, when it is easier to act on.

A practical plan

• Tell your prescriber before you stop, and ask whether a lower dose or a taper is an option.
• Start regular exercise while you are still on the medicine. Include some resistance work.
• Weigh yourself weekly once you stop. Regain is gradual and easy to miss.
• Set a trigger in advance. The DiRECT diabetes trial used regain of more than 2 kg and more than 4 kg as points to step support back up.
• Decide now what you will do at that trigger: see your GP, restart treatment, or try another approach.

What support you should expect in the UK

In August 2025 NICE updated its quality standard for overweight and obesity. It says people who stop a weight loss medicine should be offered support for at least a year afterwards. That means regular check-ins, help building routines, and an action plan to use if weight starts to return.

On the NHS, semaglutide for weight loss is prescribed through specialist services that are usually accessed for up to two years. Stopping is therefore built into the pathway. Ask early what the discharge plan is and who follows you up.

NICE standards set expectations for NHS-commissioned care. Private providers vary. Before you start with one, or before you stop, ask:

• Do you offer a lower maintenance dose, and what does it cost per month?
• Do you support tapering, and is it clinician-led?
• What follow-up do I get after my last prescription, and for how long?
• If I regain weight, can I restart, and at what dose?

Our provider directory shows which services include coaching alongside the medicine.

If the weight comes back

Regain after stopping is the expected outcome on the evidence, not a personal failure. It is also not the end of the options. You can restart treatment, usually from a low dose. You can discuss a different medicine. Or you can look at approaches that do not involve a GLP-1 at all, including surgery and supervised diet replacement, which our companion guide covers.

The bottom line

GLP-1 medicines control weight while you take them. For most people the effect fades when they stop, and the best current evidence for keeping weight off is to stay on a lower dose or switch to a tablet instead of stopping outright.

If you do stop, the strategy with the most support is regular exercise that began while you were still on treatment. Tapering may help but has not been properly tested. Monitoring and a plan will not prevent regain on their own, but they let you act on 3 kg instead of 15.

The honest answer on how to stop a GLP-1 and reliably keep the weight off is that we do not yet know.

Useful next reads

• Weight loss without GLP-1 medicines: what works, what’s modest, and what’s hype
• How much do weight loss injections cost in the UK?
• Who can get weight loss medication in the UK?
• Price pages for Mounjaro, Wegovy, the Wegovy pill and Foundayo